LBO — HONORHEALTH JOHN C. LINCOLN MED CTR
IRR: 35.0% | MOIC: 4.48x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
35.0%
IRR
4.48x
MOIC
$127.4M
Entry EV
$355.5M
Exit EV
$65.6M
Equity Invested
Sources & Uses
S&UTotal · $127.4M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $49.5M | 38.8% | |
| Sub Debt | $12.4M | 9.7% | |
| Equity | $65.6M | 51.5% | |
| Enterprise Value | $123.7M | 97.1% | |
| Transaction Fees | $3.7M | 2.9% | |
| Total Uses | $127.4M | 100.0% |
Interpretation
INTAt 4.48x MOIC and 35.0% IRR over 5 years, this deal exceeds the typical 20% hurdle — strong candidate.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $33.9M |
| Exit Ev | $355.5M |
| Net Debt At Exit | $61.8M |
| Equity At Exit | $293.7M |
| Equity Invested | $65.6M |
| Total Value Created | $228.1M |
| Value From Growth | $225.6M |
| Value From Multiple | $6.2M |
| Value From Deleveraging | 0.0% |